Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy M Miller

Showing results (111-120 of 128) with videos related to

Pageof 13
Sort By:
Molecular Neurodegeneration|May 15, 2025
Network analysis of the cerebrospinal fluid proteome reveals shared and unique differences between sporadic and familial forms of amyotrophic lateral sclerosisAdam N Trautwig, Edward J Fox, Eric B Dammer, et al.
JAMA Neurology|February 9, 2026
Long-Term Tofersen in SOD1 Amyotrophic Lateral SclerosisTimothy M Miller, Merit E Cudkowicz, Pamela J Shaw, et al.
Nucleic Acids Research|July 2, 2025
Elucidating brain transport pathways and cell type-dependent gene silencing of a durable lipid-siRNA conjugate administered into cerebrospinal fluidAlexander G Sorets, Katrina R Schwensen, Nora Francini, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|June 5, 2016
Defining SOD1 ALS natural history to guide therapeutic clinical trial designTaha Bali, Wade Self, Jingxia Liu, et al.
JAMA Neurology|March 24, 2025
Reldesemtiv in Amyotrophic Lateral Sclerosis: Results From the COURAGE-ALS Randomized Clinical TrialJeremy M Shefner, Merit E Cudkowicz, Angela Genge, et al.
Neurology|October 4, 2019
Prospective natural history study of <i>C9orf72</i> ALS clinical characteristics and biomarkersAlexander J Cammack, Nazem Atassi, Theodore Hyman, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|June 12, 2025
Hospitalizations as an outcome measure in COURAGE-ALSStacy A Rudnicki, Ammar Al-Chalabi, Jinsy A Andrews, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|May 31, 2023
COURAGE-ALS: a randomized, double-blind phase 3 study designed to improve participant experience and increase the probability of successJeremy M Shefner, Ammar Al-Chalabi, Jinsy A Andrews, et al.
JAMA Neurology|July 6, 2026
Antisense Oligonucleotide Tofersen Distribution in the Central Nervous System of SOD1-ALS Autopsy Tissue DonorsAmanda J Guise, Monica Thanawala Sellon, Shanu F Roemer, et al.
Science Translational Medicine|December 20, 2019
Human genetics and neuropathology suggest a link between miR-218 and amyotrophic lateral sclerosis pathophysiologyIrit Reichenstein, Chen Eitan, Sandra Diaz-Garcia, et al.
Pageof 13

Showing results (111-120 of 128) with videos related to

Sort By:
Pageof 13
Molecular Neurodegeneration|May 15, 2025
Network analysis of the cerebrospinal fluid proteome reveals shared and unique differences between sporadic and familial forms of amyotrophic lateral sclerosisAdam N Trautwig, Edward J Fox, Eric B Dammer, et al.
JAMA Neurology|February 9, 2026
Long-Term Tofersen in SOD1 Amyotrophic Lateral SclerosisTimothy M Miller, Merit E Cudkowicz, Pamela J Shaw, et al.
Nucleic Acids Research|July 2, 2025
Elucidating brain transport pathways and cell type-dependent gene silencing of a durable lipid-siRNA conjugate administered into cerebrospinal fluidAlexander G Sorets, Katrina R Schwensen, Nora Francini, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|June 5, 2016
Defining SOD1 ALS natural history to guide therapeutic clinical trial designTaha Bali, Wade Self, Jingxia Liu, et al.
JAMA Neurology|March 24, 2025
Reldesemtiv in Amyotrophic Lateral Sclerosis: Results From the COURAGE-ALS Randomized Clinical TrialJeremy M Shefner, Merit E Cudkowicz, Angela Genge, et al.
Neurology|October 4, 2019
Prospective natural history study of <i>C9orf72</i> ALS clinical characteristics and biomarkersAlexander J Cammack, Nazem Atassi, Theodore Hyman, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|June 12, 2025
Hospitalizations as an outcome measure in COURAGE-ALSStacy A Rudnicki, Ammar Al-Chalabi, Jinsy A Andrews, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|May 31, 2023
COURAGE-ALS: a randomized, double-blind phase 3 study designed to improve participant experience and increase the probability of successJeremy M Shefner, Ammar Al-Chalabi, Jinsy A Andrews, et al.
JAMA Neurology|July 6, 2026
Antisense Oligonucleotide Tofersen Distribution in the Central Nervous System of SOD1-ALS Autopsy Tissue DonorsAmanda J Guise, Monica Thanawala Sellon, Shanu F Roemer, et al.
Science Translational Medicine|December 20, 2019
Human genetics and neuropathology suggest a link between miR-218 and amyotrophic lateral sclerosis pathophysiologyIrit Reichenstein, Chen Eitan, Sandra Diaz-Garcia, et al.
Pageof 13